)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Denali Therapeutics
Denali Therapeutics (DNLI) investor relations material
Denali Therapeutics Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary3 Nov, 2026
Executive summary
AVLAYAH generated $17.8M in Q3 net product revenue in its second full commercial quarter; Q4 guidance is $30.0M–$32.0M.
Q3 net income was $70.1M, including a $194.0M net gain from the Priority Review Voucher sale; September-end cash, equivalents and marketable securities totaled $1.01B.
Zafinofusp alfa and multiple TransportVehicle programs have 2027 milestones or data readouts planned.
Financial highlights
Q3 revenue was $17.8M versus none in Q3 2025; 9M revenue was $21.4M versus none in 9M 2025.
Q3 operating loss was $126.8M versus $137.4M; 9M operating loss was $394.6M versus $418.0M.
9M net loss was $185.9M versus $384.0M; Q3 EPS was $0.37 basic and diluted versus a $0.74 loss.
Q3 R&D expense was $106.1M and SG&A was $37.5M; 9M R&D was $307.0M and SG&A was $107.3M.
9M operating cash use was $345.6M; ending cash, equivalents and restricted cash was $106.0M, alongside $1.0B in cash, equivalents and marketable securities.
Outlook and guidance
Q4 2026 AVLAYAH net product revenue guidance is $30.0M–$32.0M; management cautioned Q3’s step-up is not a run rate.
Zafinofusp alfa BLA submission seeking accelerated approval remains planned for 2027; additional Phase 1/2 data are expected in Q1 2027, subject to manufacturing readiness.
Initial clinical data are expected in 2027 for Alzheimer’s programs DNL628 and DNL921; COMPASS data are expected in H1 2028.
2027 data are expected from DNL593, DNL628, DNL921, DNL952 and DNL151; DNL593 and DNL628 data are expected in H1.
Through 2028, goals include two growing commercial brands, five clinical proofs of concept and four to six additional programs entering the clinic.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Denali Therapeutics
- AVLAYAH's launch validates a brain-targeted biologics platform, driving pipeline and global expansion.DNLI
Morgan Stanley 24th Annual Global Healthcare Conference - AVYLAH's strong launch and a robust pipeline position the company for major growth by 2027.DNLI12th Annual Cantor Fitzgerald Global Healthcare Conference
- Transformative BBB-penetrant therapies drive growth, with AVLAYAH leading a $1B+ opportunity.DNLICorporate presentation
- AVLAYAH's launch drove $3.6M revenue, $195M PRV sale, and Q3 guidance of $10–12M.DNLIQ2 2026
- DNL310 targets accelerated approval in early 2025, with broad pipeline and platform expansion underway.DNLIMorgan Stanley 22nd Annual Global Healthcare Conference
- AVLAYAH’s strong launch and differentiated platform set the stage for major milestones by 2027.DNLIGoldman Sachs 47th Annual Global Healthcare Conference 2026
- All agenda items passed, including director elections and auditor ratification.DNLIAGM 2026
- Two near-term launches and $275M funding accelerate growth in BBB-enabled rare disease therapies.DNLIInvestor Day 2025
- Accelerated FDA path for DNL310 drives portfolio momentum in neurodegeneration and rare diseases.DNLI2024 Cantor Fitzgerald Global Healthcare Conference
Next Denali Therapeutics earnings date
Stifel 2026 Healthcare Conference 202611 Nov, 2026
Denali Therapeutics
Next Denali Therapeutics earnings date
Stifel 2026 Healthcare Conference 202611 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Denali Therapeutics Inc is a biotechnology company focused on developing therapies for neurodegenerative diseases. The company researches and creates treatments targeting conditions such as Alzheimer's disease, Parkinson’s disease, and other disorders affecting the central nervous system. Denali Therapeutics operates within the healthcare and biotechnology sectors. The company is headquartered in South San Francisco, California, and its shares are listed on the NASDAQ.